LANSING, Mich., May 9, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched two new assays for the detection of natural toxins, Reveal® Q+ for DON EndPoint and Reveal Q+ for Aflatoxin EndPoint.
The Reveal Q+ EndPoint assays are easy-to-use quantitative lateral flow tests that provide accurate results in minutes. Designed to be read on Neogen's Raptor® Solo Platform, the EndPoint assays are intended for use in situations where increased workflow output is needed.
"The new EndPoint assays take our trusted Reveal Q+ assays to the next level, providing users with an efficient way to test large sample volumes for the presence of natural toxins," said John Adent, Neogen's President and CEO. "As we continually look for ways to make workflows simpler for our customers, we are pleased to offer this new solution to help make the testing process easier, while delivering accurate results."
Both assays have received a Federal Grain Inspection Service (FGIS) Certificate of Compliance for corn and wheat commodities, certifying that the tests meet all of the USDA-FGIS's design and performance standards and can be used for official inspections.
Neogen offers the most comprehensive range of food safety diagnostic test products for foodborne bacteria, mycotoxins, food allergens, and other concerns. Its full line of mycotoxin test kits detects aflatoxin, deoxynivalenol (DON), fumonisin, ochratoxin, T-2/HT-2, and zearalenone.
About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
CONTACT: Mary Gadola, Senior Product Manager, Immunodiagnostics and Natural Toxins
800.234.5333 ext. 2289, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.39 |
Daily Change: | -0.21 -4.57 |
Daily Volume: | 12,316,827 |
Market Cap: | US$952.370M |
January 21, 2025 January 10, 2025 December 17, 2024 October 10, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load